Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
talimogene laherparepvec + pembrolizumab
- Development stage
- Phase 3
- Lead developer
- Amgen
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intralesional (talimogene Laherparepvec), Intravenous (pembrolizumab)
01
Overview
This drug is a combination therapy consisting of **talimogene laherparepvec (T-VEC)**, an *oncolytic herpes simplex virus type-1 immunotherapy* engineered to selectively replicate within tumors and express granulocyte-macrophage colony-stimulating factor (GM-CSF), and **pembrolizumab**, a *monoclonal antibody checkpoint inhibitor* targeting programmed cell death protein 1 (PD-1)[1][5][6][7]. T-VEC promotes local tumor cell lysis and stimulates an anti-tumor immune response, while pembrolizumab blocks the inhibitory PD-1 receptor on T cells, enhancing immune-mediated tumor elimination[5][6][7]. This combination has been investigated in clinical trials for advanced melanoma, head and neck squamous cell carcinoma, and sarcomas, aiming to synergistically augment anti-tumor immunity beyond either agent alone[1][2][3][4][5][6].
- Other names
- talimogene laherparepvec + pembrolizumabT-VEC + pembrolizumab
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)PDCD1 (Programmed cell death protein 1 receptor)GM-CSF (Granulocyte-macrophage colony-stimulating factor)
Beyond the preview
Go deeper on talimogene laherparepvec + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on talimogene laherparepvec + pembrolizumab.